GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyell Immunopharma Inc (NAS:LYEL) » Definitions » Asset Turnover

Lyell Immunopharma (Lyell Immunopharma) Asset Turnover : 0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Lyell Immunopharma Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Lyell Immunopharma's Revenue for the three months ended in Dec. 2023 was $0.01 Mil. Lyell Immunopharma's Total Assets for the quarter that ended in Dec. 2023 was $772.51 Mil. Therefore, Lyell Immunopharma's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Lyell Immunopharma's annualized ROE % for the quarter that ended in Dec. 2023 was -31.31%. It is also linked to ROA % through Du Pont Formula. Lyell Immunopharma's annualized ROA % for the quarter that ended in Dec. 2023 was -27.41%.


Lyell Immunopharma Asset Turnover Historical Data

The historical data trend for Lyell Immunopharma's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyell Immunopharma Asset Turnover Chart

Lyell Immunopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
- 0.01 0.01 0.08 -

Lyell Immunopharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 - - - -

Competitive Comparison of Lyell Immunopharma's Asset Turnover

For the Biotechnology subindustry, Lyell Immunopharma's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lyell Immunopharma's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyell Immunopharma's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Lyell Immunopharma's Asset Turnover falls into.



Lyell Immunopharma Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Lyell Immunopharma's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0.13/( (937.561+750.029)/ 2 )
=0.13/843.795
=0.00

Lyell Immunopharma's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0.013/( (794.989+750.029)/ 2 )
=0.013/772.509
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Lyell Immunopharma  (NAS:LYEL) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Lyell Immunopharma's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-211.72/676.2625
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-211.72 / 0.052)*(0.052 / 772.509)*(772.509/ 676.2625)
=Net Margin %*Asset Turnover*Equity Multiplier
=-407153.85 %*0.0001*1.1423
=ROA %*Equity Multiplier
=-27.41 %*1.1423
=-31.31 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Lyell Immunopharma's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-211.72/772.509
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-211.72 / 0.052)*(0.052 / 772.509)
=Net Margin %*Asset Turnover
=-407153.85 %*0.0001
=-27.41 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Lyell Immunopharma Asset Turnover Related Terms

Thank you for viewing the detailed overview of Lyell Immunopharma's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Lyell Immunopharma (Lyell Immunopharma) Business Description

Traded in Other Exchanges
N/A
Address
201 Haskins Way, South San Francisco, CA, USA, 94080
Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors).
Executives
Richard Klausner director, officer: Executive Chairman 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Matthew Lang officer: Chief Business Officer C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Rahsaan Thompson officer: Chief Legal Officer 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Tina M. Albertson officer: Chief Medical Officer C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080
Gary K. Lee officer: Chief Scientific Officer C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080
Cathy Friedman director C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Arch Venture Fund Ix Overage, L.p. 10 percent owner 8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Elizabeth Homans director, officer: Chief Executive Officer C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080
Stephen J. Hill officer: Chief Technical Ops. Officer C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080
Charles W. Newton officer: Chief Financial Officer 46 FREDRICK AVENUE, ATHERTON CA 94027
Otis W Brawley director 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Elizabeth G Nabel director BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115
William Jl Rieflin director NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Arch Venture Partners Ix, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Ix, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631